29A:FRA
Amphastar Pharmaceuticals, Inc
€22.94
arrow_downward
-0.56%(-0.13) 1D
Oct 19, 10:00:00 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 29A...
Open
€22.66
High
€22.94
Low
€22.66
Mkt. cap
1.11B
Avg. vol.
0.00
Volume
0.00
52-wk high
€24.68
52-wk low
€13.90
No. of employees
2K
Open
€22.66
High
€22.94
Low
€22.66
Mkt. cap
1.11B
Avg. vol.
0.00
Volume
0.00
52-wk high
€24.68
52-wk low
€13.90
No. of employees
2K
News stories
From web sources and news partners
BigGo Finance
·
11 minutes ago
Dow Falls 36 Points for Second Straight Session as Oil Rally Weighs, AI-Related Buying Provides Support
Bloomberg
·
56 minutes ago
US Stock Futures Edge Higher After Chipmaker Rally: Markets Wrap
TradingView
·
55 minutes ago
Nasdaq Jumps Past 1 Percent as VIX Swings While Dow Dips Below Its 50-Day Line
Investing.com
·
2 hours ago
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.07%
Profile
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.
In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn. Wikipedia
About Amphastar Pharmaceuticals, Inc
CEO-
Employees1.98K
Founded1996
HeadquartersRancho Cucamonga, California, United States
SectorPharmaceutical industry
Websiteamphastar.com